NHS Weight Loss Injections: Access, Eligibility, and the Latest Treatments

The National Health Service (NHS) in England is now prescribing weight loss medications to eligible patients living with obesity, alongside guidance on reduced calorie diets and increased physical activity. Recent approvals and phased rollout plans are expanding access to these treatments, but understanding the criteria and available options is crucial. This article provides a comprehensive overview of weight management injections available through the NHS, eligibility requirements, and the latest developments.

What Weight Loss Medications are Available on the NHS?

Currently, the NHS prescribes several types of weight loss medications. These fall into the category of Glucagon-like peptide-1 receptor agonists (GLP-1s). These medications work by mimicking a natural hormone released after eating, helping individuals feel fuller and reducing appetite.

• Tirzepatide (Mounjaro®): Recommended by NICE in December 2024, tirzepatide is a novel dual GIP/GLP-1 receptor agonist for managing overweight and obesity with weight-related comorbidities.
• GLP-1 Receptor Agonists (Wegovy® and Saxenda®): Previously, these medications were only available in secondary care, but access is expanding.
• Other GLP-1 medicines: Semaglutide (Ozempic, Rybelsus, Wegovy), liraglutide, and dulaglutide (Trulicity) are also licensed GLP-1 medicines available in the UK.

Who is Eligible for Weight Loss Injections on the NHS?

Access to these medications is not universal. The NHS prioritizes patients based on clinical need. NICE has directed NHS England to prioritize a cohort of 220,000 patients over the first 3 years of a 12-year rollout. Eligibility generally includes:

• Living with obesity: Typically defined as having a Body Mass Index (BMI) of 35 or higher.
• Weight-related health problems (comorbidities): Such as type 2 diabetes, cardiovascular disease, or other serious health conditions.
• Commitment to lifestyle changes: Medication is prescribed alongside a reduced-calorie diet and increased physical activity.

The Phased Rollout and Access to Treatment

The introduction of tirzepatide and expanded access to other GLP-1 agonists require new services and training for healthcare professionals. NHS England is implementing a phased approach to manage demand, train staff, and build an evidence base for sustainable delivery of weight management services.

Access to medication is provided in combination with a reduced calorie diet and increased physical activity, as outlined in the final NICE guidance. The full commissioning guidance will be issued after an evaluation of the initial 3-year rollout.

Supply Issues and Current Status

The NHS previously faced supply issues with GLP-1 agonists, impacting access for some patients. However, stocks were resupplied at the complete of December 2024, and this issue has reportedly been resolved. If you are still experiencing difficulties accessing your prescribed medication, contact your healthcare team.

How do GLP-1 agonists work?

GLP-1 agonists increase the levels of incretins – hormones – which help the body produce more insulin when needed and lowers blood sugar levels. They also slow down how quickly food is digested and can reduce your appetite, so you eat less.

Where to Find More Information

• NHS England: Medicines for Obesity
• National Institute for Health and Care Excellence (NICE): NICE Guidelines
• Diabetes UK: GLP-1 agonists
• UK Government: GLP-1 medicines for weight loss and diabetes

Key Takeaways

• The NHS is expanding access to weight loss medications, primarily GLP-1 agonists, for eligible patients.
• Eligibility criteria include a BMI of 35 or higher and weight-related health problems.
• Treatment requires a commitment to lifestyle changes, including diet and exercise.
• A phased rollout is underway to manage demand and ensure sustainable delivery of services.